To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.

• Status: Not yet recruiting
• Trial end date: 2024-12-30
• Target enrollment: 0
• Participant gender: All

Summary

The study is to optimize the clinical therapeutic pathway of peginterferon alfa-2a treatment in patients with chronic hepatitis B based on the detection of interferon gene mutation (IFNA2p.Ala120Thr) and interferon-stimulated genes (ISGs) detection gene spectrum.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Collaborator: First People's Hospital of Foshan
• Treatments: Interferon alpha-2; Interferon-alpha; Interferons; Peginterferon alfa-2b

Criteria

Inclusion Criteria:

• Age between 18 and 65 years old;

• HBsAg positive, HBsAg quantification≤1500 IU/mL;

• Serum HBV DNA quantification <100 IU/mL;

• HBeAg negative.

Exclusion Criteria:

• Treated with interferon in the past six months;

• Liver cirrhosis or HCC and other associated tumors;

• Women during pregnancy or lactation;

• With liver disease caused by other causes;

• Combination infection of HIV or other immunodeficiency diseases;

• With diabetes, autoimmune diseases and other organ dysfunction or failure;

• Combination of other serious complications (infection, hepatic encephalopathy,gastrointestinal bleeding, hepatorenal syndrome, etc.);

• Others who cannot be treated with interferon;

• Anyone cannot return to the hospital for follow-up and follow-up visits regularly as planned